T45.AX3

Clinical Causes: Use of immune checkpoint inhibitors such as nivolumab, pembrolizumab, or atezolizumab Administration of immunostimulant drugs like interferons or interleukins Improper dosing or accidental overdose of these medications Adverse reactions due to individual sensitivity or allergic responses

Key Symptoms: Severe fatigue or weakness Difficulty breathing or shortness of breath Unusual or persistent cough Swelling or inflammation in different parts of the body Gastrointestinal issues like nausea, vomiting, diarrhea, or abdominal pain Fever or chills Skin rashes, redness, or itching Muscle or joint pain Confusion, headache, or dizziness Signs of organ dysfunction, such as abnormal liver or kidney function

Diagnosis Path: Diagnosing poisoning caused by immune checkpoint inhibitors or immunostimulant drugs involves a combination of medical history, physical examination, and laboratory tests. Healthcare providers may review the patient's medication history to identify recent or current use of these drugs. Blood tests can help evaluate organ function and identify markers of inflammation or immune response. Imaging studies might be performed if internal organ damage is suspected. In addition, healthcare professionals will rule out other causes of symptoms to establish a clear link between medication use and the adverse effects.

Treatment Protocols: Treatment typically involves stopping or adjusting the medication responsible for poisoning. Supportive care is essential and may include medications to manage symptoms such as pain, inflammation, or allergic reactions. In more severe cases, corticosteroids or other immunosuppressive drugs might be administered to reduce immune system overactivity. Hospitalization may be necessary for monitoring and managing serious adverse effects. The focus of treatment is to alleviate symptoms, prevent complications, and support the recovery of affected organs. It is vital for patients to communicate openly with their healthcare providers about any symptoms experienced during treatment with these medications.